{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Is Daxor Corp. technically bullish or bearish?
As of June 17, 2025, Daxor Corp. shows a neutral trend with mixed signals, as weekly indicators are bullish while daily moving averages are mildly bearish, suggesting a consolidation phase.
Who are in the management team of Daxor Corp.?
As of March 2022, the management team of Daxor Corp. includes Mr. Michael Feldschuh (Chairman, President, CEO), Mr. Jonathan Feldschuh (Chief Scientific Officer), and several directors: Henry Cremisi, Edward Feuer, Joy Goudie, James Lombard, and Robert Willens.
What does Daxor Corp. do?
Daxor Corporation is an investment company specializing in medical instrumentation and biotechnology, primarily focused on developing the Blood Volume Analyzer (BVA) -100. As of December 2011, it reported net sales of $0 million and a net profit of -$1 million, with a market cap of $43.53 million.
How big is Daxor Corp.?
As of Jun 18, Daxor Corp. has a market capitalization of 43.53 million, with net sales of 1.45 million and a net profit of -7.18 million over the last four quarters. The company has shareholder's funds of 35.79 million and total assets of 36.63 million as of Dec 24.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
